| Closed |
S1500 |
PhII: MET inhibitors for papillary RCC |
4/5/2016 |
|
100% |
|
|
| Closed |
S1513 |
RPh II of 2nd Line FOLFIRI w/ or w/o Veliparib (ABT888) in met panc cancer |
9/1/2016 |
|
86% |
|
|
| Closed |
S1512 |
Desmoplastic study |
10/20/2016 |
|
100% |
|
|
| Open |
S1609 |
DART |
1/13/2017 |
|
98% |
|
|
| Closed |
S1605 |
Ph II Atezolizumab Local Bladder |
2/7/2017 |
|
85% |
|
|
| Closed |
S1616 |
Ipilimumab + Nivolmab in Adv Melanoma follow prog on PD-1 Inhibitor |
7/17/2017 |
|
100% |
|
|
| Open |
S1608 |
Randomized Ph II for Relapsed Refractory FL |
8/10/2017 |
|
81% |
|
|
| Open |
S1501 |
Carvedilol vs No Trt in Prevention of Cardiac Dysfunction in HER-2+ mBrCa |
9/15/2017 |
|
38% |
|
|
| Closed |
S1612 |
Older AML |
12/22/2017 |
|
5% |
|
|
| Open |
S1803 |
PIII Daratumumab + Lenalidomide Post-Auto SCT Maint for MM |
6/27/2019 |
|
100% |
|
|
| Closed |
S1712 |
Rando PhII Ruxolitinib + BCR-ABL TKIs in CML w/Molecular Disease |
7/20/2018 |
|
96% |
|
|
| Open |
S1703 |
Disease Monitoring Study |
7/16/2018 |
|
45% |
|
|
| Open |
S1905 |
PI/II OBI-3424 for R/R T-ALL/T-LBL |
8/17/2020 |
|
22% |
|
|
| Open |
S1706 |
Phase II Rando, Double Blind Placebo/Veliparib + RT for Inflammatory Breast |
9/12/2018 |
|
51% |
|
|
| Open |
S1802 |
PhIII Rando SST v. SST+Surgery or Radiation for Met Prostate Cancer |
9/17/2018 |
|
62% |
|
|
| Open |
LUNGMAP |
LUNGMAP Screening Protocol for NSCLC |
1/28/2019 |
|
|
|
|
| Closed |
S1900A |
LUNGMAP S1900A: LOH HIGH and/or BRCA 1/2 mutation - Rucaparib |
1/29/2019 |
|
73% |
|
|
| Closed |
S1714 |
CIPN |
3/1/2019 |
|
100% |
|
|
| Closed |
S1806 |
Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer. |
4/19/2019 |
|
100% |
|
|
| Closed |
S1916 |
Digital Medicine for Opioid Pain Control |
6/11/2019 |
|
3% |
|
|
